<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733122</url>
  </required_header>
  <id_info>
    <org_study_id>2008_016</org_study_id>
    <secondary_id>V501-034</secondary_id>
    <nct_id>NCT00733122</nct_id>
  </id_info>
  <brief_title>Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)</brief_title>
  <official_title>Evaluation of Tolerability and Immunogenicity of GARDASIL in Healthy Females, Between 16 and 26 Years of Age, in India.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study is designed to determine the tolerability and immunogenicity of a 3-dose regimen
      of Gardasil administered to healthy married females between 16 and 23 years of age, in India.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of subjects who seroconvert to each of HPV 6, 11, 16, 18 at Week 4 Post dose 3 (Month 7), Month 24 and Month 36.</measure>
    <time_frame>Week 4 Post dose 3 (Month 7), Month 24 and Month 36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titers (GMTs)</measure>
    <time_frame>Week 4 Post dose 3 (Month 7), Month 24 and Month 36</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Married Females Between 16 And 23 Years Of Age With Intact Uteri

          -  No Clinical Evidence Of Gross Purulent Cervicitis (Otherwise Postpone Until After
             Treatment Or Lack Of Laboratory Confirmation Of Treatable Cause

          -  Must Agree To Refrain From Sexual Activity (Including Vaginal And Anal Penetration And
             Any Genital Contact) For 48 Hours Prior To Any Scheduled Visit That Includes A Pelvic
             Examination In An Attempt To Avoid Detection Of Viral DNA Which Has Been Deposited In
             The Vagina Or On The Perineal/Perianal Area During Sexual Intercourse And Is Not The
             Result Of Ongoing Infection

          -  Not Pregnant Now (As Determined By A Serum Pregnancy Test Or Urine Pregnancy Test
             Sensitive To 25 IU/L hCG), And Must Agree To Use Effective Contraception Through Month
             7 Of The Study

          -  Must Agree To Provide Study Personnel With A Primary Telephone Number As Well As An
             Alternate Telephone Number For Follow-Up Purposes.

          -  Individuals Who Have Had Sexual Intercourse In The 2 Weeks Prior To Enrollment Must
             Have Been Using Effective Contraception As Defined Above (Emergency Contraception Is
             Not Considered Effective Contraception For Enrollment Into The Study.)

        Exclusion Criteria:

          -  Individuals Concurrently Enrolled In Clinical Studies Of Investigational Agents Or
             Studies Involving Collection Of Cervical/Genital Specimens

          -  Feverish Feeling Within 24 Hours Prior To The First Injection And No Temperature &lt;
             100°F Or &lt; 37.8°C (Oral Or Oral Equivalent) At First Vaccination

          -  History Of Recent Or Ongoing Alcohol Or Other Drug Abuse. Alcohol Abusers Are Defined
             As Those Who Drink Despite Recurrent Social, Interpersonal, And Legal Problems As A
             Result Of Alcohol Use

          -  History Of Known Prior Vaccination With An Hpv Vaccine Subject Has Received
             Non-Replicating (Inactivated) Vaccine Within 14 Days Prior To The Day 1 Vaccination Or
             Has Received Replicating (Live Virus) Vaccine Within 21 Days Prior To The Day 1
             Vaccination

          -  Individuals With Any Prior Abnormal Pap Test Showing Squamous Intraepithelial Lesion
             (Sil), Ascus, Asc-Us, Asc-H Individuals With A History Of Genital Warts

          -  Individuals Allergic To Any Vaccine Component, Including Aluminium, Yeast, Or
             Benzonase™ (Nuclease, Nycomed [Used To Remove Residual Nucleic Acids From This And
             Other Vaccines])

          -  Individuals Who Have Received Any Immune Globulin Preparation Or Blood-Derived
             Products Within The 3 Months Prior To The First Injection, Or Plan To Receive Any
             Through The Completion Of The Study

          -  Individuals With A History Of Splenectomy, Known Immune Disorders (E.G., Systemic
             Lupus Erythematosus, Rheumatoid Arthritis), Or Receiving Immunosuppressives (E.G.,
             Substances Or Treatments Known To Diminish Immune Response Such As Radiation Therapy,
             Administration Of Antimetabolites, Antilymphocytic Sera, Systemic Corticosteroids)

          -  Individuals Who Have Received Periodic Treatments With Immunosuppressives, Defined As
             At Least 3 Courses Of Systemic Corticosteroids Each Lasting At Least 1 Week In
             Duration For The Year Prior To Enrollment, Will Be Excluded. Subjects Using Topical
             Steroids (I.E., Inhaled Or Nasal) Will Be Eligible For Vaccination

          -  Individuals Who Are Immunocompromised Or Have Been Diagnosed As Having HIV Infection

          -  Individuals With Known Thrombocytopenia Or Any Coagulation Disorder That Would
             Contraindicate Intramuscular Injections

          -  Any Condition Which In The Opinion Of The Investigator Might Interfere With The
             Evaluation Of The Study Objectives

          -  Any Plans To Permanently Relocate From The Area Prior To The Completion Of The Study
             Or To Leave For An Extended Period Of Time When Study Visits Would Need To Be
             Scheduled

          -  Inability To Give Consent/Assent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2008</study_first_posted>
  <last_update_submitted>January 13, 2011</last_update_submitted>
  <last_update_submitted_qc>January 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Vice President of Late Stage Development</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

